Extended treatment trial for rare immune disease halted
Disease control
Terminated
This study aimed to provide long-term treatment with CDZ173 to patients with APDS/PASLI, a rare genetic immune disorder. It followed patients who had previously participated in related studies to monitor the drug's safety and effectiveness over time. The study was terminated and …
Phase: PHASE2, PHASE3 • Sponsor: Pharming Technologies B.V. • Aim: Disease control
Last updated Apr 02, 2026 10:12 UTC